Dishonest adoption of phonetically similar pharmaceutical marks precludes prior user defense and warrants permanent injunction

The Plaintiff, a French pharmaceutical company, is the registered proprietor of the trademark PLAVIX (word mark and device) used for an anti-thrombosis drug containing 'Clopidogrel'

The marks were registered with effect from 1995 and 1998, with a global launch in 1998 and an Indian launch in 2003

In 2008, the Plaintiff discovered the Defendants were using the mark CLAVIX for an identical preparation and filed a suit for infringement and passing off

The Defendants claimed they bona fidely adopted the mark in 2001, deriving 'CL' from the salt name and 'AVIX' from the therapeutic indication "Atherosclerotic Vascular Incidences"

1. Whether the Plaintiff is the registered proprietor of the mark PLAVIX?

2. Whether the Defendants' use of the mark CLAVIX constitutes infringement and/or passing off?

3. Whether the Defendants are entitled to the defense of prior user under Section 34 of the Trade Marks Act?

4. Whether the suit is barred by delay or laches?

Section 29 of the Trade Marks Act, 1999 regarding infringement, where deceptive similarity between marks for identical goods triggers statutory relief

Kaviraj Pandit Durga Dutt Sharma v. Navaratna Pharmaceutical Laboratories, distinguishing that in infringement, added features like packaging differences are immaterial if the essential features are adopted

Stricter approach for medicinal products was derived from Cadila Health Care v. Cadila Pharmaceuticals, emphasizing that similarity in medicines can be life-threatening

Section 34 of the Act was interpreted via Bodhisattva Charitable Trust v. Mayo Foundation, requiring the defendant's use to pre-date both the plaintiff's registration and user

The Court found the marks PLAVIX and CLAVIX to be structurally and phonetically similar, differing by only a single letter

Regarding infringement, the Court noted that since the Plaintiff's registrations dated back to 1995 and 1998, the Defendants' 2001 use did not meet the "prior to registration" requirement of Section 34

The Court deemed the Defendants' adoption dishonest; the explanation for coining the mark was "far-fetched" as the term "Atherosclerotic Vascular Incidences" does not exist in standard medical literature

The Court also highlighted the Defendants’ failure to conduct a trademark search before launching

The claim for passing off failed because the Plaintiff could not prove sufficient "spillover reputation" in India specifically in 2001 (the time of Defendants' launch), applying the territoriality principle from Toyota v. Prius

Delay was excused as the Plaintiff was entitled to wait until the infringement posed a significant commercial threat, and equity does not assist a dishonest adopter

The Court granted a permanent injunction restraining the Defendants from using CLAVIX or any deceptively similar mark

The Court awarded nominal damages of Rs. 20,00,000/- for the injury caused by infringement and the continuous use of the mark during the litigation

The Plaintiff was also awarded actual costs of the suit, to be determined by the Taxation Officer